

Amendments to the Claim:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-50 (cancelled).

51. (Currently Amended) A method of reducing the risk of infection associated with an organ transplantation comprising ~~a use of administration of an effective amount of~~ mannan-binding lectin (MBL) ~~for the treatment of a patient suffering from systemic inflammatory response syndrome (SIRS) and/or to a patient in need of organ transplantation and/or for reducing the risk in a patient of acquiring SIRS,~~ whereby the risk of infection associated with such organ transplantation is reduced, said MBL comprising one or more human MBL proteins which may be the same or different, said human MBL proteins comprising one or more human MBL protein monomers of about 96kDa, each monomer consisting of three identical human MBL polypeptide chains, each chain of about 32 kD.

52-53. (Cancelled).

54. (Previously Presented) The method according to claim 51, wherein the patient is critically ill, wherein a critically ill patient is a patient which has sustained or are at risk of sustaining acutely life-threatening single or multiple organ system failure due to disease or injury, a patient who is being operated and where complications supervene, and a patient who has been operated in a vital organ within the last week or subject to major surgery within the last week.

55. (Previously Presented) The method according to claim 51, wherein said MBL treatment is administered to increase the survival rate in the intensive care unit (ICU).

56. (Currently Amended) The method according to claim 51, wherein said MBL treatment is administered to reduce the time

that a patient stays within the hospital, ~~for example within the intense care unit.~~

57. (Previously Presented) The method according to claim 54, wherein the patient suffers from post-surgical critical illness.

58. (Previously Presented) The method according to claim 54, wherein the patient suffers from post-traumatic critical illness.

59-60 (Cancelled)

61. (Currently Amended) The method according to claim ~~51~~ 63, wherein ~~said MBL comprises oligomers, wherein said oligomers may be the same or different, and are preferably independently selected from the group of oligomers consisting of trimers, tetramers, pentamers and/or and hexamers of said about 96kDa MBL protein monomer.~~

62. (Currently Amended) The method according to claim 51, wherein the MBL comprises at least one MBL protein which is a mannan-binding lectin (MBL) polypeptide monomer protein of about 96 kDa, consisting of a single MBL protein monomer, said monomer consisting of three identical about 32 kDa MBL polypeptide chains, ~~or at least one mannan-binding lectin (MBL) polypeptide oligomer comprising or at least one mannan-binding lectin (MBL) polypeptide monomer.~~

63. (Currently Amended) The method according to claim 51, wherein said MBL protein comprises at least one mannan-binding lectin (MBL) polypeptide oligomer comprising at least one a plurality of mannan-binding lectin (MBL) polypeptide protein monomers, each of about 96 kDa, each monomer consisting of three identical about 32 kDa MBL polypeptide chains.

64. (Currently Amended) The method according to claim 51, wherein the ~~medicament~~ MBL is used in such way that the blood MBL level in the patient is kept above 250 ng/ml.

65. (Currently Amended) The method according to claim 51, wherein the ~~medicament~~ MBL is used in such way that the blood MBL level in the patient is kept above 500 ng/ml.

66. (Currently Amended) The method according to claim 51, wherein the ~~medicament~~ MBL is used in such way that the blood MBL level in the patient is kept above 1000 ng/ml.

67. (Currently Amended) The method according to claim 51, wherein the ~~medicament~~ MBL is used in such way that the blood MBL level in the patient is kept between 1000 ng/ml and 2000 ng/ml.

68-70. (Cancelled)

71. (Previously Presented) The method according to claim 51, wherein the patient has MBL polypeptide serum levels below a predetermined minimum MBL polypeptide serum level, wherein the predetermined level is a concentration of 500 ng/ml.

72. (Previously Presented) The method according to claim 51, wherein said treatment is to reduce the risk of a fatal outcome during intensive care treatment of an individual.

73. (New) The method of claim 51, wherein there is an increased risk of systemic inflammatory response syndrome (SIRS) as a result of said increased risk of infection following transplantation, and hence by reducing the risk of infection the MBL reduces the risk of SIRS.

74. (New) A method for reducing the risk of at least one adverse condition associated with an organ transplantation, whose risk is reduced by prophylactic or therapeutic treatment with mannan-binding lectin, which comprises administering to a patient in need of an organ transplant, or who has received an organ transplant, a mannan-binding lectin (MBL), in such amount and in such manner as to reduce said risk said MBL comprising one or more human MBL proteins which may be the same or different, said human MBL proteins comprising one or more human MBL protein monomers of about 96kDa, each monomer consisting of three identical human MBL polypeptide chains, each chain of about 32 kDa.

75. (New) The method of claim 74 wherein at least one such adverse condition is infection subsequent to the organ

transplantation.

76. (New) The method of claim 51 in which the MBL is administered prior to infection.

77. (New) The method of claim 51 in which the MBL is administered for amelioration of an infection.

78. (New) The method of claim 51 in which MBL is administered during transplantation.

79. (New) The method of claim 51 in which the MBL is administered after transplantation.

80. (New) The method according to claim 74, wherein said MBL protein comprises at least one mannan-binding lectin (MBL) oligomer comprising a plurality of mannan-binding lectin (MBL) protein monomers, each of about 96 kDa, consisting of three about 32 kDa polypeptide chains.

81. (New) The method according to claim 80, wherein said oligomers may be the same or different, and are independently selected from the group of oligomers consisting of trimers, tetramers, pentamers and hexamers of said about 96kDa MBL protein monomer.

82. (New) The method according to claim 74, wherein said treatment is to reduce the risk of a fatal outcome during intensive care treatment of an individual.

83. (New) The method of claim 74 in which the MBL is administered after transplantation.

84. (New) The method according to claim 51 wherein said MBL consists essentially only of MBL protein oligomers, each oligomer consisting of two or more MBL 96 kDa protein monomers.

85. (New) The method according to claim 74 wherein said MBL consists essentially only of MBL protein oligomers, each oligomer consisting of two or more MBL 96 kDa protein monomers.